Clare Hughes

Chairperson, Chief Executive Officer & Founding Director – (MPSI BSC. PHARM)

Clare is the co-founder and CEO of Telenostic. Prior to founding Telenostic, Clare founded two other successful pharmaceutical companies: CF Pharma, a developer of pharmaceutical and veterinary products, and NutriScience, a producer of nutraceuticals for the veterinary market, which she sold to the Belgian veterinary
harmaceutical company, Ecuphar.

Clare hails from the famous Hughes dynasty, renowned throughout the world as producers of top sport horses, showjumpers and racehorses. Clare holds a degree in pharmacy.


Trish McOwan

Product Development Director & Founding Director

Trish is the co-founder and Product Development Director at Telenostic. Trish has over 15 years’ experience in the veterinary medicine market establishing and operating point of care facilities to service the growing and expanding Irish market.

Trish was previously a project manager at CF Pharma in Ireland. Trish has overseen and led the product development of the Telenostic system to date. Trish has led the IP partnership with University College Dublin, the patent submission, the successful Smart Agri Project and secured the ‘Gold Seal of Approval’ from the European Commission in 2021 for the Telenostic Horizon 2020 submission.


Billy Power

Chief Financial Officer – (F.C.I.M.A)

Billy is an experienced Accountant who previously held the position of Director and General Manager of Waterford Crystal Ltd for seven years and Managing Director for three years. At the time Waterford Crystal was the largest anufacturing company in Ireland with 3,700 employees. After retiring from Waterford Crystal Billy set up his own business mentoring and advising small and medium size businesses and in the last twenty years he has advised over 400 businesses, 15 of which were long term assignments (10 years plus). With many of these long term companies raising finance was an issue and he has raised funds through the B.E.S./ E.I.I.S scheme for over 17 clients.


David Tiffney

Non-Executive Director / Investor Representative

David Tiffney has more than 25 years’ experience in the global pharmaceutical, dietary supplement and food industries covering commercial, operations, manufacturing, quality, and regulatory compliance. In addition, David’s breadth of knowledge and contacts across APAC, the Americas and Europe has seen he and his team invest in start-ups across these regions with significant successful divestments. David brings to the Telenostic board executive experience in business strategy, capital funding, M&A and exits


Tim White

Non-Executive Director and Strategic Advisor – (PGDip.Mgt; M.Mgt; FAICD; JP)

Tim has over 25 years of experience in animal health including biotechnology, diagnostics, pathology, SaaS, life sciences and pharmaceutical sectors. With extensive experience leading business strategy, business development, sales, marketing, technical operations and supply chain in growth companies, with S&P 500 experience.

Prior to joining the Telenostic Board, Tim was the Managing Director – Regional General Manager for IDEXX Inc. Responsible for two (2) country subsidiaries, and was on the Global Commercial Leadership Team. His extensive in-depth industry and sector knowledge provides Telenostic with unique insights to accelerate commercialisation of the Telenostic products.

Tim is a Fellow of the Australian Institute of Company Directors, Justice of the Peace (NSW), with a Master of Management from MGSM (Finance & Marketing) – based in Sydney, Australia.


Henry Brankin

Non-Executive Director

Henry is the current Chief Executive Officer at Virtual Access (Ireland) Limited part of the Westermo Group and formerly as a Group Manager at BT telecommunications.

Henry is an Executive Business Manager with 30 years’ experience in the telecommunications and IT sector. Henry’s areas of specialty are systems architecture, new product development, new product launch and general business management.

Henry is a strong leader, with an eye for detail and a pragmatic approach to developing products. His proven ability to manage both growth and challenging market conditions makes him a valued board member.